Response to infliximab is related to disease duration in paediatric Crohn's disease.

Lionetti, P; Bronzini, F; Salvestrini, C; Bascietto, C; Canani, R Berni; Dé Angelis, G L; Guariso, G; Martelossi, S; Papadatou, B; Barabino, A

Lionetti, P; Bronzini, F; Salvestrini, C; Bascietto, C; Canani, R Berni; Dé Angelis, G L; Guariso, G; Martelossi, S; Papadatou, B; Barabino, A.

Affiliation

Lionetti P; Dipartimento di Pediatria, Università di Firenze-Ospedale Meyer, Florence, Italy.

Aliment Pharmacol Ther ; 18(4): 425-31, 2003 Aug 15.

Article in En | MEDLINE | ID: mdl-12940928

Subject(s)

Antibodies, Monoclonal/administration & dosage; Crohn Disease/drug therapy; Gastrointestinal Agents/administration & dosage; Intestinal Fistula/complications; Adolescent; Antibodies, Monoclonal/adverse effects; Child; Child, Preschool; Crohn Disease/complications; Female; Follow-Up Studies; Gastrointestinal Agents/adverse effects; Humans; Infliximab; Infusions, Intravenous; Intestinal Fistula/drug therapy; Male; Retrospective Studies; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Gastrointestinal Agents / Crohn Disease / Intestinal Fistula / Antibodies, Monoclonal Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Child / Child, preschool / Female / Humans / Male Language: En Journal: Aliment Pharmacol Ther Journal subject: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2003 Document type: Article Affiliation country: Italy Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links